Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Sandoz Expands Biosimilar Production in Lendava, Boosting EU Strategic Autonomy

Discover how Sandoz’s new Lendava biosimilar hub uses advanced PAT technology to boost EU production, meet 2040 Bio100 goals, and enhance patient access.

Dr. Michael Chen

01/10/2026, 04:11

4 minutes to read

How Missouri’s Roundup Design‑Defect Trial Could Redefine Bayer’s Glyphosate Liability and Investor Confidence

Missouri jury weighs Roundup design‑defect claims; Bayer’s €7 bn settlement and EPA’s new review may reshape glyphosate liability and investor confidence.

Dr. Michael Chen

01/10/2026, 01:11

5 minutes to read

Danaher Corp: Accelerating Growth with Precision Diagnostics & Strategic M&A

Discover how Danaher Corp’s precision diagnostics and strategic M&A fuel growth, cutting costs & improving patient outcomes—insights for investors & clinicians.

Dr. Michael Chen

30/09/2026, 20:10

4 minutes to read

How Eli Lilly’s Zepbound & Foundayo Outperform Competitors in Obesity & Diabetes

Discover Eli Lilly’s new obesity and diabetes drugs: tirzepatide (Zepbound) beats Wegovy for weight loss and oral forglipron rivals semaglutide in blood‑sugar control.

Dr. Michael Chen

30/09/2026, 13:43

4 minutes to read

Novo Nordisk Secures Global Rights to Weekly Oral Obesity Pill Targeting GLP‑1 & GIP Receptors

Discover Novo Nordisk’s worldwide license for HRS‑1596, a weekly oral dual‑agonist obesity pill targeting GLP‑1 and GIP receptors, promising improved adherence and weight‑loss efficacy.

Dr. Michael Chen

30/09/2026, 06:05

5 minutes to read

Merck Secures Global License for Oral KRAS G12D Inhibitor, Boosting Oncology Portfolio

Merck’s global license for SPR2015, a pre‑clinical oral KRAS G12D inhibitor, could add a $2.13 bn‑value precision therapy to its oncology line‑up.

Dr. Michael Chen

30/09/2026, 01:24

4 minutes to read

United Therapeutics CEO Exercises Options & Sells Shares Under Structured Trading Plan

United Therapeutics shares: CEO’s option exercise, conversion and structured sales reveal clear, compliant insider activity and market‑impact‑minimizing liquidity management.

Dr. Michael Chen

29/09/2026, 23:33

2 minutes to read

FDA Grants FDA Approval to Oral SMAD2/3 Inhibitor for Progressive Heterotopic Ossification

FDA approves oral SMAD2/3 inhibitor, giving HO patients a once‑daily, targeted therapy that cuts bone growth by 38% and offers new hope for rare musculoskeletal disease.

Dr. Michael Chen

27/09/2026, 20:17

3 minutes to read

Inside Natera’s Share‑Holding Shuffle: Trusts, Trading Plans, and Insider Transparency

Explore Natera’s latest insider share‑holding adjustments, detailing direct sales and trust transfers—insight into governance, pricing strategy, and tax planning.

Dr. Michael Chen

27/09/2026, 06:33

4 minutes to read

Illumina’s Rising Shares Reflect Strong Genomics Innovation, Market Resilience

Illumina’s rising share price reflects its leadership in high‑accuracy NGS platforms, bioinformatics, and clinical trials—fueling investor confidence in genomic‑driven healthcare innovation.

Dr. Michael Chen

26/09/2026, 06:18

5 minutes to read

Older articles